1. Home
  2. ADVM

ADVM

Adverum Biotechnologies Inc.

Logo Adverum Biotechnologies Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Founded: 2006 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 239.3M IPO Year: 2014
Target Price: $40.00 AVG Volume (30 days): 277.2K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -11.60 EPS Growth: N/A
52 Week Low/High: $7.10 - $29.70 Next Earning Date: 05-09-2024
Revenue: $3,600,000 Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: